Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.
CCL20
anti-mitochondrial M2 antibody
primary biliary cholangitis
pulmonary artery hypertension
systemic sclerosis
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
20
02
2021
received:
02
12
2020
accepted:
06
03
2021
pubmed:
23
3
2021
medline:
1
12
2021
entrez:
22
3
2021
Statut:
ppublish
Résumé
Systemic sclerosis (SSc) is a chronic autoimmune disease resulting in vasculopathy and fibrosis of the skin and major internal organs. Especially, interstitial lung disease and pulmonary arterial hypertension are the leading causes of mortality. C-C motif ligand 20 (CCL20) is known as a homeostatic and inflammatory chemokine, which is associated with fibrosis and angiogenesis and constantly expressed in organs involved in SSc. Therefore, we investigated the potential contribution of CCL20 to the development of SSc. We conducted cross-sectional analyses of 67 SSc patients and 20 healthy controls recruited in a single center for 9 years. Serum CCL20 levels were measured by enzyme-linked immunosorbent assay. Statistical analyses were performed with the Mann-Whitney U test, the Kruskal-Wallis test followed by Dunn's multiple comparison test, Fisher's exact probability test and the Spearman's rank correlation coefficient. SSc patients had significantly higher serum CCL20 levels than healthy controls. In SSc patients, serum CCL20 levels correlated inversely with the percentage of predicated diffusion lung capacity for carbon monoxide and positively with mean pulmonary artery pressure (mPAP). In addition, SSc patients with increased serum CCL20 levels had anti-mitochondrial antibody M2 titer significantly elevated relative to those with normal levels, and SSc patients with asymptomatic primary biliary cholangitis (PBC) possessed higher serum CCL20 levels than those without. Importantly, serum CCL20 levels were associated positively with mPAP values and PBC presence by multivariate regression analysis. Serum CCL20 levels may be involved in the development of pulmonary vascular involvement leading to pulmonary arterial hypertension and asymptomatic PBC in SSc patients.
Identifiants
pubmed: 33750014
doi: 10.1111/1756-185X.14103
doi:
Substances chimiques
Biomarkers
0
CCL20 protein, human
0
Chemokine CCL20
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-718Subventions
Organisme : Ministry of Health, Labor, and Welfare of Japan
ID : grant for Research in Intractable Diseases
Informations de copyright
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Asano Y. Systemic sclerosis. J Dermatol. 2018;45:128-138.
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685-1699.
Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002.
Toki S, Motegi S, Yamada K, et al. Demographic and clinical features of autoimmune thyroid disorder in Japanese patients with systemic sclerosis. J Dermatol. 2014;41:1053-1057.
Zheng B, Vincent C, Fritzler MJ, et al. Prevalence of systemic Sclerosis in primary biliary cholangitis using the new ACR/EULAR classification criteria. J Rheumatol. 2017;44:33-39.
Distler JH, Feghali-Bostwick C, Soare A, et al. Review: frontiers of antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol. 2017;69:257-267.
Noda S, Asano Y, Nishimura S, et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun. 2014;5:5797.
Stone MJ, Hayward JA, Huang C, et al. Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci. 2017;18:342.
Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409-426.
King J, Abraham D, Stratton R. Chemokines in systemic sclerosis. Immunol Lett. 2018;195:68-75.
Tao J, Li L, Tan Z, et al. Up-regulation of CC chemokine ligand 20 and its receptor CCR6 in the lesional skin of early systemic sclerosis. Eur J Dermatol. 2011;21:731-736.
Hasegawa M. Biomarkers in systemic sclerosis: their potential to predict clinical courses. J Dermatol. 2016;43:29-38.
van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Eng J Med. 2014;370:433-443.
Hasegawa M, Asano Y, Endo H, et al. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2013;23:1076-1084.
Ito T, Carson WF, Cavassani KA, et al. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res. 2011;317:613-619.
Ranasinghe R, Eri R. Modulation of the CCR6-CCL20 axis: a potential therapeutic target in inflammation and cancer. Medicina (Kaunas). 2018;54:88.
Comerford I, Bunting M, Fenix K, et al. Prospects & Overviews An immune paradox: How can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. BioEssays. 2010;32:1067-1076.
Ranasinghe R, Eri R. Pleiotropic immune functions of chemokine receptor 6 in health and disease. Medicines (Basel). 2018;5:69.
Affò S, Morales-Ibanez O, Rodrigo-Torres D, et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut. 2014;63:1782.
Shi T, Zhang T, Zhang L, et al. The distribution and the fibrotic role of elevated inflammatory Th17 cells in patients with primary biliary cirrhosis. Medicine (Baltimore). 2015;94:e1888.
Guo W, Li H, Liu H, et al. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncol Rep. 2019;42:1075-1089.
Benkheil M, Van Haele M, Roskams T, et al. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): potential role in HCV-related liver cancer. Exp Cell Res. 2018;372:168-177.
Cc Z, Chen C, Zq XU, et al. CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):387-397.
Almanzar G, Klein M, Schmalzing M, et al. Disease manifestation and inflammatory activity as modulators of Th17/Treg balance and RORC/FoxP3 methylation in systemic sclerosis. Int Arch Allergy Immunol. 2016;171:141-154.
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737-2747.
LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892-1896.
Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865-870.
Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48:516-522.
Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340-1349.
Koga T, Otomo K, Mizui M, et al. Calcium/Calmodulin-dependent kinase IV facilitates the recruitment of interleukin-17-producing cells to target organs through the CCR6/CCL20 axis in Th17 cell-driven inflammatory diseases. Arthritis Rheumatol. 2016;68:1981-1988.
Pan Z, Marra AM, Benjamin N, et al. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther. 2019;21:1-15.
Marsigliante S, Vetrugno C, Muscella A. Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. Mol Carcinog. 2016;55:1175-1186.
Soto B, Gallastegi-Mozos T, Rodríguez C, et al. Circulating CCL20 as a new biomarker of abdominal aortic aneurysm. Sci Rep. 2017;7:17331.
Bridgewood C, Stacey M, Alase A, et al. IL-36γ has proinflammatory effects on human endothelial cells. Exp Dermatol. 2017;26:402-408.
Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015;37:489-500.
Harada K, Shimoda S, Ikeda H, et al. Significance of periductal Langerhans cells and biliary epithelial cell-derived macrophage inflammatory protein-3α in the pathogenesis of primary biliary cirrhosis. Liver Int. 2011;31:245-253.
Norman GL, Bialek A, Encabo S, et al. Is prevalence of PBC underestimated in patients with systemic sclerosis? Dig Liver Dis. 2009;41:762-764.
Caramaschi P, Biasi D, Volpe A, et al. Coexistence of systemic sclerosis with other autoimmune diseases. Rheumatol Int. 2007;27:407-410.
Hamaguchi Y, Sumida T, Kawaguchi Y, et al. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. J Dermatol. 2017;44:13-17.